KR102193823B1 - 하이브리드 경쇄 마우스 - Google Patents

하이브리드 경쇄 마우스 Download PDF

Info

Publication number
KR102193823B1
KR102193823B1 KR1020207015360A KR20207015360A KR102193823B1 KR 102193823 B1 KR102193823 B1 KR 102193823B1 KR 1020207015360 A KR1020207015360 A KR 1020207015360A KR 20207015360 A KR20207015360 A KR 20207015360A KR 102193823 B1 KR102193823 B1 KR 102193823B1
Authority
KR
South Korea
Prior art keywords
mouse
human
light chain
gene
gene segments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207015360A
Other languages
English (en)
Korean (ko)
Other versions
KR20200064166A (ko
Inventor
린 맥도날드
션 스티븐스
케이건 규레르
앤드류 제이. 머피
캐롤리나 에이. 호시아와
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Priority to KR1020207036106A priority Critical patent/KR102320944B1/ko
Publication of KR20200064166A publication Critical patent/KR20200064166A/ko
Application granted granted Critical
Publication of KR102193823B1 publication Critical patent/KR102193823B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207015360A 2010-06-22 2011-06-22 하이브리드 경쇄 마우스 Active KR102193823B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207036106A KR102320944B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35731410P 2010-06-22 2010-06-22
US35731710P 2010-06-22 2010-06-22
US61/357,317 2010-06-22
US61/357,314 2010-06-22
PCT/US2011/041370 WO2011163314A1 (en) 2010-06-22 2011-06-22 Hybrid light chain mice

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197012527A Division KR102118565B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207036106A Division KR102320944B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스

Publications (2)

Publication Number Publication Date
KR20200064166A KR20200064166A (ko) 2020-06-05
KR102193823B1 true KR102193823B1 (ko) 2020-12-22

Family

ID=44509861

Family Applications (16)

Application Number Title Priority Date Filing Date
KR1020187036183A Active KR101975884B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020187036167A Active KR101970944B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020227037565A Pending KR20220150430A (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020207036106A Active KR102320944B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020137001582A Active KR101934852B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020197002903A Active KR102001430B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020197012527A Active KR102118565B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020237006658A Pending KR20230036157A (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020217017823A Active KR102462042B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020137001586A Active KR101945352B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020197017074A Active KR102059909B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020197002870A Active KR101991234B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020197037332A Active KR102211911B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020217034867A Active KR102506001B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020217002982A Active KR102266097B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020207015360A Active KR102193823B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스

Family Applications Before (15)

Application Number Title Priority Date Filing Date
KR1020187036183A Active KR101975884B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020187036167A Active KR101970944B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020227037565A Pending KR20220150430A (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020207036106A Active KR102320944B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020137001582A Active KR101934852B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020197002903A Active KR102001430B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020197012527A Active KR102118565B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020237006658A Pending KR20230036157A (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020217017823A Active KR102462042B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020137001586A Active KR101945352B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020197017074A Active KR102059909B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020197002870A Active KR101991234B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020197037332A Active KR102211911B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020217034867A Active KR102506001B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020217002982A Active KR102266097B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스

Country Status (30)

Country Link
US (22) US9012717B2 (enExample)
EP (7) EP3205726A1 (enExample)
JP (16) JP6009441B2 (enExample)
KR (16) KR101975884B1 (enExample)
CN (4) CN104404050B (enExample)
AU (1) AU2011271046B2 (enExample)
BR (3) BR122020013427B1 (enExample)
CA (2) CA2804311C (enExample)
CY (5) CY1117537T1 (enExample)
DK (5) DK2568049T3 (enExample)
ES (5) ES2646052T3 (enExample)
HR (5) HRP20160497T1 (enExample)
HU (5) HUE044001T2 (enExample)
IL (12) IL313063A (enExample)
LT (4) LT2568049T (enExample)
ME (5) ME02444B (enExample)
MX (6) MX336344B (enExample)
MY (6) MY195212A (enExample)
NO (1) NO2905338T3 (enExample)
NZ (6) NZ626979A (enExample)
PL (5) PL2905338T3 (enExample)
PT (5) PT2480675T (enExample)
RS (5) RS55042B1 (enExample)
RU (3) RU2601297C2 (enExample)
SG (4) SG186390A1 (enExample)
SI (5) SI3034608T1 (enExample)
SM (5) SMT201700506T1 (enExample)
TR (1) TR201905992T4 (enExample)
WO (2) WO2011163314A1 (enExample)
ZA (5) ZA201300062B (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR101987351B1 (ko) 2008-09-30 2019-06-10 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
RU2011129459A (ru) 2008-12-18 2013-01-27 Эрасмус Юниверсити Медикал Сентр Роттердам Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
DK2505654T4 (da) 2010-02-08 2020-07-27 Regeneron Pharma Mus med fælles letkæde
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PL2553100T3 (pl) 2010-03-31 2018-03-30 Ablexis, Llc Inżynieria genetyczna zwierząt nie będących ludźmi w celu wytworzenia przeciwciał chimerycznych
RU2601297C2 (ru) * 2010-06-22 2016-10-27 Ридженерон Фармасьютикалз, Инк. Мыши, экспрессирующие гибридную легкую цепь иммуноглобулина
AU2011286185B2 (en) 2010-07-26 2014-08-14 Trianni, Inc. Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CA3250882A1 (en) * 2010-08-02 2025-11-29 Regeneron Pharamaceuticals, Inc. Mice that Make Binding Proteins Comprising VL Domains
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
WO2013041844A2 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
EP3741862A1 (en) * 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102081657B1 (ko) 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
ES2665793T3 (es) 2012-03-16 2018-04-27 Regeneron Pharmaceuticals, Inc. Anticuerpos de cadena ligera modificada mediante ingeniería genética con histidina y roedores modificados genéticamente para la generación de los mismos
NZ730271A (en) 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
CN104302170B (zh) 2012-03-16 2016-09-28 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP2831245A1 (en) 2012-03-28 2015-02-04 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
ES2678221T3 (es) 2013-02-20 2018-08-09 Regeneron Pharmaceuticals, Inc. Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas
LT3501272T (lt) * 2013-03-13 2023-03-27 Regeneron Pharmaceuticals, Inc. Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką
PL2967012T3 (pl) 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
SG10201810825YA (en) * 2013-09-18 2019-01-30 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
WO2015103999A1 (en) * 2014-01-10 2015-07-16 Hung Alfur Fu-Hsin Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
RU2017113134A (ru) 2014-09-19 2018-10-19 Регенерон Фармасьютикалз, Инк. Химерные антигенные рецепторы
CN106999566B (zh) 2014-10-03 2022-01-28 麻省理工学院 结合埃博拉病毒糖蛋白的抗体及其用途
LT3221363T (lt) 2014-11-21 2020-08-10 Bristol-Myers Squibb Company Antikūnai prieš cd73 ir jų panaudojimas
PT3233912T (pt) 2014-12-19 2021-08-09 Regenesance B V Antocorpos que se ligam a c6 humano e utilizações destes
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
PT3254035T (pt) 2015-02-05 2019-05-13 Basf Se Central de energia solar com um primeiro circuito de transferência de calor e um segundo circuito de transferência de calor
CA2979702A1 (en) * 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP6797137B2 (ja) 2015-05-29 2020-12-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｏｘ４０に対する抗体およびその使用
EP3313886A1 (en) 2015-06-29 2018-05-02 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
ES2926969T3 (es) 2015-11-19 2022-10-31 Bristol Myers Squibb Co Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
US11053288B2 (en) 2016-02-04 2021-07-06 Trianni, Inc. Enhanced production of immunoglobulins
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
CA3016534A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
EA039084B1 (ru) 2016-05-09 2021-12-01 Бристол-Майерс Сквибб Компани Антитела к tl1a и их применения
JP7324583B2 (ja) 2016-05-20 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法
PT3462853T (pt) 2016-06-03 2023-04-21 Regeneron Pharma Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US10650241B2 (en) * 2016-06-27 2020-05-12 Facebook, Inc. Systems and methods for identifying matching content
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
US11267873B2 (en) 2016-10-13 2022-03-08 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
US12063913B2 (en) 2016-10-31 2024-08-20 National University Corporation Tottori University Human antibody-producing non-human animal and method for preparing human antibodies using same
DK3766343T3 (da) * 2016-11-04 2022-06-20 Regeneron Pharma Ikke-humane dyr med et manipuleret immunoglobulin-lambda-letkædelocus
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CN116058333A (zh) 2017-12-05 2023-05-05 瑞泽恩制药公司 具有经工程改造的免疫球蛋白λ轻链的非人动物以及所述非人动物的用途
CN120192415A (zh) 2018-01-12 2025-06-24 百时美施贵宝公司 抗tim3抗体及其用途
KR102761890B1 (ko) 2018-03-23 2025-02-06 브리스톨-마이어스 스큅 컴퍼니 Mica 및/또는 micb에 대한 항체 및 그의 용도
LT3772927T (lt) 2018-03-24 2025-02-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės arba žiurkės, skirtos gaminti terapinius antikūnus prieš peptidų- mhc kompleksus, jų gamybos būdai ir panaudojimas
CN116420679B (zh) 2018-03-26 2025-10-03 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
EP3801010B1 (en) * 2018-06-08 2025-01-01 Crystal Bioscience Inc. Transgenic chicken for producing diversified antibodies that have the same light chain i
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP7594440B2 (ja) 2018-10-26 2024-12-04 ビークルエナジージャパン株式会社 電池制御装置
MY205758A (en) 2018-11-16 2024-11-12 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
KR102570405B1 (ko) 2019-01-22 2023-08-25 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
CA3127153A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
KR20220016880A (ko) * 2019-06-05 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 카파 유전자좌에서 발현된 제한적 람다 경쇄 레퍼토리를 갖는 비-인간 동물 및 이의 용도
CN114554841B (zh) * 2019-07-01 2024-06-11 特里安尼公司 转基因哺乳动物及其使用方法
KR20220110233A (ko) 2019-12-02 2022-08-05 리제너론 파마슈티칼스 인코포레이티드 펩티드-mhc ii 단백질 작제물 및 그의 용도
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
AU2020454777A1 (en) * 2020-06-25 2023-02-02 Humab Co., Ltd. Heterozygous transgenic animal
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
IL303865A (en) 2020-12-23 2023-08-01 Regeneron Pharma Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
CN121079326A (zh) 2023-05-04 2025-12-05 诺瓦森塔股份有限公司 抗cd161抗体及其使用方法
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026373A1 (en) 1998-11-03 2000-05-11 Babraham Institute MURINE EXPRESSION OF HUMAN Igμ LOCUS
JP2005510253A (ja) 2001-11-30 2005-04-21 アブジェニックス インコーポレイテッド ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
EP2314625B1 (en) * 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) * 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
CN1789416B (zh) * 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
ES2473596T3 (es) 2003-07-15 2014-07-07 Therapeutic Human Polyclonals, Inc. Loci de inmunoglobulina humanizada
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
RU2398777C2 (ru) * 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
PT2767161T (pt) 2004-10-19 2018-04-20 Regeneron Pharma Método para gerar um animal homozigótico para uma modificação genética
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP2061812A4 (en) * 2006-08-22 2010-06-09 G2 Inflammation Pty Ltd METHOD FOR THE PRODUCTION OF ANTIBODIES
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
CA2721231C (en) * 2008-04-14 2015-10-06 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
WO2009143472A2 (en) 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
KR101987351B1 (ko) * 2008-09-30 2019-06-10 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
RU2011129459A (ru) * 2008-12-18 2013-01-27 Эрасмус Юниверсити Медикал Сентр Роттердам Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
DK2505654T4 (da) * 2010-02-08 2020-07-27 Regeneron Pharma Mus med fælles letkæde
AU2011266843C9 (en) 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
RU2601297C2 (ru) * 2010-06-22 2016-10-27 Ридженерон Фармасьютикалз, Инк. Мыши, экспрессирующие гибридную легкую цепь иммуноглобулина

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026373A1 (en) 1998-11-03 2000-05-11 Babraham Institute MURINE EXPRESSION OF HUMAN Igμ LOCUS
JP2005510253A (ja) 2001-11-30 2005-04-21 アブジェニックス インコーポレイテッド ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Exp Med. 1999 May 17; 189(10): 1611-1620.

Also Published As

Publication number Publication date
IL313063A (en) 2024-07-01
IL269078A (en) 2019-11-28
JP2019033765A (ja) 2019-03-07
RU2590594C2 (ru) 2016-07-10
ZA201300062B (en) 2014-09-25
US20150246977A1 (en) 2015-09-03
ME02442B (me) 2016-09-20
US20160060359A1 (en) 2016-03-03
US20170107484A1 (en) 2017-04-20
AU2011271043A9 (en) 2015-10-01
EP2480676A1 (en) 2012-08-01
ZA201404600B (en) 2015-09-30
CY1122877T1 (el) 2021-05-05
IL300712B1 (en) 2024-07-01
AU2011271043B2 (en) 2015-10-01
AU2011271046B2 (en) 2015-10-01
HRP20160497T1 (hr) 2016-07-15
JP2018023403A (ja) 2018-02-15
KR20200143511A (ko) 2020-12-23
SI2480675T1 (sl) 2016-08-31
LT2905338T (lt) 2017-12-27
US9163092B2 (en) 2015-10-20
HUE044001T2 (hu) 2019-09-30
US20150246976A1 (en) 2015-09-03
US20150351371A1 (en) 2015-12-10
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
NZ627119A (en) 2015-05-29
HUE036597T2 (hu) 2018-07-30
SG10201504568YA (en) 2015-07-30
NO2905338T3 (enExample) 2017-12-30
EP2905338A1 (en) 2015-08-12
JP6073441B2 (ja) 2017-02-01
SI2568049T1 (sl) 2016-10-28
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
CA2804311A1 (en) 2011-12-29
US20150089680A1 (en) 2015-03-26
ES2570131T3 (es) 2016-05-17
HUE029692T2 (en) 2017-03-28
EP2905338B8 (en) 2018-01-24
NZ605751A (en) 2014-10-31
US20150176002A1 (en) 2015-06-25
KR20190073584A (ko) 2019-06-26
JP2017012204A (ja) 2017-01-19
KR101970944B1 (ko) 2019-04-23
US20190153384A1 (en) 2019-05-23
RU2724736C2 (ru) 2020-06-25
JP6341972B2 (ja) 2018-06-13
EP3034608A1 (en) 2016-06-22
MY157477A (en) 2016-06-15
US20140137275A1 (en) 2014-05-15
CY1119478T1 (el) 2018-03-07
CA2803864A1 (en) 2011-12-29
MY195217A (en) 2023-01-11
HUE029691T2 (en) 2017-03-28
KR20200064166A (ko) 2020-06-05
CY1117537T1 (el) 2017-04-26
KR102506001B1 (ko) 2023-03-07
CA2804311C (en) 2017-09-12
KR20190014578A (ko) 2019-02-12
TR201905992T4 (tr) 2019-05-21
KR20180135996A (ko) 2018-12-21
US9399683B2 (en) 2016-07-26
US9035128B2 (en) 2015-05-19
ZA201300063B (en) 2014-09-25
KR20230036157A (ko) 2023-03-14
CN104404050B (zh) 2018-06-08
US9006511B2 (en) 2015-04-14
DK2480676T3 (en) 2016-06-20
CN103068993A (zh) 2013-04-24
CN104342455A (zh) 2015-02-11
NZ605758A (en) 2014-08-29
EP2905338B1 (en) 2017-08-02
EP2480675A1 (en) 2012-08-01
EP3205726A1 (en) 2017-08-16
HK1183321A1 (en) 2013-12-20
BR112012032991B1 (pt) 2021-08-10
SMT201700506T1 (it) 2018-01-11
KR101991234B1 (ko) 2019-06-20
BR112012032991A8 (pt) 2020-09-29
KR102001430B1 (ko) 2019-07-18
JP2016010417A (ja) 2016-01-21
RS55037B1 (sr) 2016-12-30
WO2011163314A1 (en) 2011-12-29
HRP20190807T1 (hr) 2019-08-23
CA2803864C (en) 2017-05-16
IL244450A0 (en) 2016-04-21
PT2480675T (pt) 2016-07-11
ZA201506598B (en) 2017-03-29
JP6545773B2 (ja) 2019-07-17
PT2480676E (pt) 2016-06-09
SG10201504324UA (en) 2015-07-30
PL2480676T3 (pl) 2016-10-31
KR102462042B1 (ko) 2022-11-03
LT2480675T (lt) 2016-10-10
US20120070861A1 (en) 2012-03-22
MY194456A (en) 2022-11-30
RS55042B1 (sr) 2016-12-30
US20120073004A1 (en) 2012-03-22
EP2568049B1 (en) 2016-04-13
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
JP2018201527A (ja) 2018-12-27
US9206262B2 (en) 2015-12-08
ES2576928T3 (es) 2016-07-12
EP2568049A1 (en) 2013-03-13
DK2905338T3 (da) 2017-11-06
HUE030285T2 (en) 2017-05-29
JP6009441B2 (ja) 2016-10-19
ES2646052T3 (es) 2017-12-11
SG186390A1 (en) 2013-01-30
IL282872A (en) 2021-06-30
HRP20160865T1 (hr) 2016-10-07
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
JP6243384B2 (ja) 2017-12-06
IL291301B2 (en) 2023-07-01
US9029628B2 (en) 2015-05-12
EP2480675B1 (en) 2016-04-06
KR102211911B1 (ko) 2021-02-05
SMT201600212B (it) 2016-08-31
US9334333B2 (en) 2016-05-10
JP2025027148A (ja) 2025-02-26
IL223719A (en) 2016-10-31
US9540452B2 (en) 2017-01-10
US20150320023A1 (en) 2015-11-12
CN103068993B (zh) 2016-01-06
US9394373B2 (en) 2016-07-19
PL3034608T3 (pl) 2019-08-30
JP2016010415A (ja) 2016-01-21
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
KR20220150430A (ko) 2022-11-10
MX2022002117A (es) 2022-03-17
CN103068994A (zh) 2013-04-24
SI2905338T1 (sl) 2017-12-29
CY1118126T1 (el) 2017-06-28
SMT201600213B (it) 2016-08-31
IL259965A (en) 2018-07-31
EP3456832A1 (en) 2019-03-20
RU2013102596A (ru) 2014-07-27
US9850462B2 (en) 2017-12-26
IL259965B (en) 2019-02-28
EP2480676B1 (en) 2016-04-06
KR20190142436A (ko) 2019-12-26
AU2011271046A1 (en) 2013-01-31
US20150173331A1 (en) 2015-06-25
US9012717B2 (en) 2015-04-21
IL223720A (en) 2017-05-29
KR20180135997A (ko) 2018-12-21
SI2480676T1 (sl) 2016-10-28
MY195214A (en) 2023-01-11
CN104342455B (zh) 2017-05-31
JP2023133554A (ja) 2023-09-22
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
CN104404050A (zh) 2015-03-11
ME03386B (me) 2020-01-20
MX347322B (es) 2017-04-21
US20190203171A1 (en) 2019-07-04
DK2480675T3 (en) 2016-08-01
CN103068994B (zh) 2016-01-20
KR101945352B1 (ko) 2019-02-07
JP5988969B2 (ja) 2016-09-07
ME02444B (me) 2016-09-20
US20240327785A1 (en) 2024-10-03
US20150173332A1 (en) 2015-06-25
KR20130027555A (ko) 2013-03-15
AU2011271043A8 (en) 2016-01-21
US20170258059A1 (en) 2017-09-14
US20130323790A1 (en) 2013-12-05
JP6963542B2 (ja) 2021-11-10
IL244450A (en) 2017-11-30
IL291301A (en) 2022-05-01
DK3034608T3 (da) 2019-05-06
KR101934852B1 (ko) 2019-01-04
MY165287A (en) 2018-03-21
JP7236409B2 (ja) 2023-03-09
BR112012033248A2 (pt) 2017-11-28
PL2568049T3 (pl) 2017-03-31
RU2016119423A3 (enExample) 2019-11-19
IL247386A (en) 2017-07-31
MX347318B (es) 2017-04-21
PT3034608T (pt) 2019-05-28
SMT201600229B (enExample) 2016-08-31
US9206261B2 (en) 2015-12-08
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
BR112012032991A2 (pt) 2015-10-06
ZA201404601B (en) 2016-02-24
US20200239837A1 (en) 2020-07-30
NZ707200A (en) 2016-04-29
ME02902B (me) 2018-04-20
DK2568049T3 (en) 2016-08-01
US20160057979A1 (en) 2016-03-03
HK1226766A1 (en) 2017-10-06
KR20210134424A (ko) 2021-11-09
WO2011163311A1 (en) 2011-12-29
HRP20171666T1 (hr) 2017-12-15
IL291301B1 (en) 2023-03-01
JP2013531501A (ja) 2013-08-08
US9844212B2 (en) 2017-12-19
RU2013102595A (ru) 2014-07-27
RS58736B1 (sr) 2019-06-28
HRP20160794T1 (hr) 2016-08-12
IL300712A (en) 2023-04-01
JP2018201528A (ja) 2018-12-27
JP2020062061A (ja) 2020-04-23
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
JP2021061863A (ja) 2021-04-22
RU2601297C2 (ru) 2016-10-27
KR20210073609A (ko) 2021-06-18
EP3034608B1 (en) 2019-01-30
KR102118565B1 (ko) 2020-06-03
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
US9066502B2 (en) 2015-06-30
BR122020013427B1 (pt) 2021-08-03
US9226484B2 (en) 2016-01-05
JP2017006152A (ja) 2017-01-12
MX336344B (es) 2016-01-15
NZ626979A (en) 2015-05-29
PL2905338T3 (pl) 2018-01-31
MX2012015300A (es) 2013-05-01
US9150662B2 (en) 2015-10-06
IL255179A0 (en) 2017-12-31
MY195212A (en) 2023-01-11
KR102059909B1 (ko) 2019-12-27
IL300712B2 (en) 2024-11-01
KR20190049932A (ko) 2019-05-09
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
RS54891B1 (sr) 2016-10-31
RS56589B1 (sr) 2018-02-28
MX348942B (es) 2017-07-04
US20130326647A1 (en) 2013-12-05
KR20210013376A (ko) 2021-02-03
AU2011271043A1 (en) 2013-01-31
SG186391A1 (en) 2013-01-30
ME02440B (me) 2016-09-20
CY1117692T1 (el) 2017-05-17
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
HK1170766A1 (zh) 2013-03-08
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
IL255179B (en) 2018-06-28
SMT201900241T1 (it) 2019-05-10
JP2020128440A (ja) 2020-08-27
NZ707198A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
KR102193823B1 (ko) 하이브리드 경쇄 마우스
KR102186822B1 (ko) 인간화 경쇄 마우스
RU2833566C2 (ru) МЫШИ, ЭКСПРЕССИРУЮЩИЕ ЛЕГКУЮ ЦЕПЬ С ВАРИАБЕЛЬНОЙ ОБЛАСТЬЮ λ ЧЕЛОВЕКА И КОНСТАНТНОЙ ОБЛАСТЬЮ МЫШИ

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6